MCID: HYP739
MIFTS: 53

Hyperlipoproteinemia, Type Iv

Categories: Blood diseases, Cardiovascular diseases, Endocrine diseases, Genetic diseases, Liver diseases, Metabolic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hyperlipoproteinemia, Type Iv

MalaCards integrated aliases for Hyperlipoproteinemia, Type Iv:

Name: Hyperlipoproteinemia, Type Iv 57
Hyperlipoproteinemia Type Iv 12 73 29 44 15 70
Familial Hypertriglyceridemia 12 29 6
Fredrickson Type Iv Hyperlipoproteinemia 12
Familial Type Iv Hyperlipoproteinemia 20
Carbohydrate-Inducible Hyperlipemia 57
Carbohydrate Inducible Hyperlipemia 20
Fredrickson Type Iv Lipidaemia 12
Fredrickson Type Iv Lipidemia 12
Hyperlipoproteinemia Type 4 20
Endogenous Hyperlipidaemia 12
Vldl Hyperlipoproteinemia 12

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
heterogeneous
autosomal dominant


HPO:

31
hyperlipoproteinemia, type iv:
Inheritance autosomal dominant inheritance heterogeneous


Classifications:



External Ids:

Disease Ontology 12 DOID:1172
OMIM® 57 144600
ICD9CM 34 272.1
MeSH 44 D006953
NCIt 50 C34711
SNOMED-CT 67 154741004
ICD10 32 E78.1
MedGen 41 C0020480
SNOMED-CT via HPO 68 263681008 74728003
UMLS 70 C0020480

Summaries for Hyperlipoproteinemia, Type Iv

OMIM® : 57 On a regular diet patients with type IV hyperlipoproteinemia demonstrate increased plasma VLDL. Plasma triglycerides are persistently increased, while plasma cholesterol and phospholipids are usually within normal limits. Precocious atherosclerosis, abnormal glucose tolerance, and atheroeruptive xanthoma may occur. The disorder is undoubtedly heterogeneous and the phenotype strongly influenced by environmental factors, particularly carbohydrate and ethanol consumption. (144600) (Updated 20-May-2021)

MalaCards based summary : Hyperlipoproteinemia, Type Iv, also known as hyperlipoproteinemia type iv, is related to hyperlipidemia, familial combined, 3 and xanthoma disseminatum, and has symptoms including hypertriglyceridemic waist An important gene associated with Hyperlipoproteinemia, Type Iv is APOA5 (Apolipoprotein A5), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Metformin and Omega 3 Fatty Acid have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and kidney, and related phenotypes are hypertriglyceridemia and glucose intolerance

Wikipedia : 73 Hyperlipidemia is abnormally elevated levels of any or all lipids or lipoproteins in the blood.... more...

Related Diseases for Hyperlipoproteinemia, Type Iv

Diseases in the Hyperlipoproteinemia, Type I family:

Hyperlipoproteinemia, Type Iv Hyperlipoproteinemia, Type V
Hyperlipoproteinemia, Type Id Hyperlipoproteinemia, Type Iii

Diseases related to Hyperlipoproteinemia, Type Iv via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Related Disease Score Top Affiliating Genes
1 hyperlipidemia, familial combined, 3 30.4 LPL CETP APOE APOC3 APOC2 APOB
2 xanthoma disseminatum 30.1 APOE APOB
3 pancreatitis 30.1 LPL LMF1 APOC2 APOA5
4 peripheral artery disease 30.0 APOE APOB APOA1
5 xanthomatosis 29.9 LPL APOE APOB
6 non-alcoholic fatty liver disease 29.4 LPL APOE APOC3 APOB APOA1
7 familial hyperlipidemia 29.1 LPL CETP APOE APOC3 APOC2 APOB
8 coronary heart disease 1 28.9 LPL CETP APOE APOC3 APOB APOA5
9 lipid metabolism disorder 28.9 LPL CETP APOE APOC3 APOB APOA5
10 myocardial infarction 28.9 LPL CETP APOE APOC3 APOB APOA5
11 abetalipoproteinemia 28.8 LPL CETP APOE APOC2 APOB APOA1
12 lipoprotein quantitative trait locus 28.6 LPL CETP APOE APOC3 APOB APOA5
13 hypercholesterolemia, familial, 1 28.6 SLC10A2 LPL CETP APOE APOB APOA2
14 hypertriglyceridemia, familial 28.3 SLC10A2 LPL CREB3L3 CETP APOE APOC3
15 familial lipoprotein lipase deficiency 28.1 LPL LMF1 GPIHBP1 APOE APOC3 APOC2
16 familial hypercholesterolemia 27.9 LPL CETP APOE APOC3 APOB APOA5
17 hyperlipoproteinemia, type i 27.0 LPL LMF1 GPIHBP1 GPD1 CETP APOE
18 silent myocardial infarction 10.2 APOB APOA1
19 hyperuricemia 10.2
20 defective apolipoprotein b-100 10.2 APOE APOB
21 hypercholesterolemia, familial, 2 10.2 APOE APOB
22 acute pancreatitis 10.2
23 generalized atherosclerosis 10.2 APOE APOB
24 fetal macrosomia 10.2 APOB APOA1
25 parametritis 10.1 APOB APOA1
26 hypoalphalipoproteinemia 10.1 APOA2 APOA1
27 hereditary amyloidosis 10.1 APOA2 APOA1
28 chylomicron retention disease 10.1 SLC10A2 APOB APOA1
29 platelet glycoprotein iv deficiency 10.1 LPL APOE APOB
30 fish-eye disease 10.1 APOA2 APOA1
31 corneal degeneration 10.1 APOB APOA1
32 hepatic lipase deficiency 10.1 LPL APOE APOA1
33 cerebral atherosclerosis 10.1 APOE APOB APOA1
34 leukodystrophy, hypomyelinating, 3 10.1 APOB APOA2 APOA1
35 abdominal obesity-metabolic syndrome 1 10.1 LPL APOB APOA1
36 hypobetalipoproteinemia, familial, 2 10.1 APOC3 APOB ANGPTL3
37 apolipoprotein c-ii deficiency 10.1 LPL GPIHBP1 APOC2
38 lipoprotein glomerulopathy 10.1 APOE APOB APOA2
39 familial lcat deficiency 10.0 APOE APOA2 APOA1
40 arcus corneae 10.0 APOB APOA1 ABCG5
41 alzheimer disease 2 10.0 CETP APOE
42 lipase deficiency, combined 10.0 LPL LMF1 GPIHBP1
43 acanthosis nigricans 10.0
44 huntington disease-like 3 10.0
45 huntington disease-like 2 10.0
46 cholelithiasis 10.0
47 gout 10.0
48 hyperinsulinism 10.0
49 lipomatosis 10.0
50 adrenogenital syndrome 10.0

Comorbidity relations with Hyperlipoproteinemia, Type Iv via Phenotypic Disease Network (PDN): (show all 11)


Acute Pancreatitis Anxiety
Esophagitis First-Degree Atrioventricular Block
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome
Mitral Valve Disease Peripheral Vascular Disease
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Hyperlipoproteinemia, Type Iv:



Diseases related to Hyperlipoproteinemia, Type Iv

Symptoms & Phenotypes for Hyperlipoproteinemia, Type Iv

Human phenotypes related to Hyperlipoproteinemia, Type Iv:

31 (show all 6)
# Description HPO Frequency HPO Source Accession
1 hypertriglyceridemia 31 HP:0002155
2 glucose intolerance 31 HP:0001952
3 hypopituitarism 31 HP:0040075
4 precocious atherosclerosis 31 HP:0004416
5 increased vldl cholesterol concentration 31 HP:0003362
6 atheroeruptive xanthoma 31 HP:0001039

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Metabolic:
abnormal glucose tolerance

Skin:
atheroeruptive xanthoma

Lab:
hyperlipoproteinemia iv
increased plasma vldl
plasma triglycerides persistently increased
plasma cholesterol and phospholipids usually normal

Vascular:
precocious atherosclerosis

Misc:
phenotype environmentally influenced, esp. by carbohydrate and ethanol consumption, uremia, hypopituitarism, contraceptive steroids, and glycogen storage disease i

Clinical features from OMIM®:

144600 (Updated 20-May-2021)

UMLS symptoms related to Hyperlipoproteinemia, Type Iv:


hypertriglyceridemic waist

GenomeRNAi Phenotypes related to Hyperlipoproteinemia, Type Iv according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased LDL uptake GR00340-A-1 8.32 LPL

MGI Mouse Phenotypes related to Hyperlipoproteinemia, Type Iv:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.8 ABCG5 ANGPTL3 APOA1 APOA2 APOA5 APOB
2 liver/biliary system MP:0005370 9.23 ABCG5 ANGPTL3 APOA1 APOB APOE LMF1

Drugs & Therapeutics for Hyperlipoproteinemia, Type Iv

Drugs for Hyperlipoproteinemia, Type Iv (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 18)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2 Omega 3 Fatty Acid Phase 4
3 Clofibric Acid Phase 4 882-09-7
4 Antimetabolites Phase 4
5 Anticholesteremic Agents Phase 4
6 Hypolipidemic Agents Phase 4
7 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
8 Lipid Regulating Agents Phase 4
9 Rosuvastatin Calcium Phase 4 147098-20-2
10 Calcium, Dietary Phase 4
11
Calcium Nutraceutical Phase 4 7440-70-2 271
12
Atorvastatin Approved Phase 3 134523-00-5 60823
13
Torcetrapib Investigational Phase 3 262352-17-0 159325
14
chenodeoxycholic acid Approved Early Phase 1 474-25-9 10133
15
Mannitol Approved, Investigational Early Phase 1 69-65-8 453 6251
16 Cathartics Early Phase 1
17 Gastrointestinal Agents Early Phase 1
18 Laxatives Early Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza. Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
2 A Double-blind, Double Dummy, Phase IV, Randomized, Multicenter, Parallel Group, Placebo Controlled Trial to Evaluate the Effect of Rosuvastatin on Triglycerides Levels in Mexican Hypertriglyceridemic Patients Completed NCT00473655 Phase 4 rosuvastatin
3 Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia Completed NCT00134498 Phase 3 torcetrapib/atorvastatin;atorvastatin
4 Effects of Activation of the Farnesoid X Receptor (FXR) on Hepatic Lipid and Glucose Metabolism in Patients With the Metabolic Syndrome and Familial Forms of Hypertriglyceridemia Completed NCT00465751 Early Phase 1 chenodeoxycholic acid;placebo capsules
5 Genetic Epidemiology of Hypertriglyceridemia Completed NCT00005368
6 Effects of Exercise on Fructose-induced Postprandial Lipemia Completed NCT03173495
7 The Effect of Milk as a Recovery Beverage After Exercise on Next-day Postprandial Triglycerides Completed NCT03154216

Search NIH Clinical Center for Hyperlipoproteinemia, Type Iv

Cochrane evidence based reviews: hyperlipoproteinemia type iv

Genetic Tests for Hyperlipoproteinemia, Type Iv

Genetic tests related to Hyperlipoproteinemia, Type Iv:

# Genetic test Affiliating Genes
1 Familial Hypertriglyceridemia 29 APOA5
2 Hyperlipoproteinemia Type Iv 29

Anatomical Context for Hyperlipoproteinemia, Type Iv

MalaCards organs/tissues related to Hyperlipoproteinemia, Type Iv:

40
Liver, Heart, Kidney, Eye

Publications for Hyperlipoproteinemia, Type Iv

Articles related to Hyperlipoproteinemia, Type Iv:

(show all 39)
# Title Authors PMID Year
1
Musculoskeletal disorders associated with type-IV hyperlipoproteinaemia. 57
4115343 1972
2
Familial type IV hyperlipoproteinemia. 57
5824739 1969
3
[The becoming of reactions of lipolysis in phylogenesis. The palmitic and oleic triglycerides as substrates. Insulin, condition of normolipemia and formation of hyper lipoproteinemia type IIb, IV and V]. 61
30550084 2018
4
[Familial hyperlipoproteinemia, type IV]. 61
17824051 2007
5
[Lowering plasma homocysteine with vitamins B6, B12, and folic acid. Effect on lipids concentration in patients with secondary hyperlipoproteinemia type IV, with and without Lovastatina treatment]. 61
16786732 2006
6
The risk groups for coronary heart disease in Koreans. Assessment by distribution of serum lipid concentrations. 61
10616751 1999
7
Risk of asymptomatic and symptomatic gallstones in moderately obese women: a longitudinal follow-up study. 61
8995952 1997
8
[Lipid status in patients on a chronic hemodialysis program]. 61
9132551 1997
9
[Serum phospholipids in patients in a chronic hemodialysis program]. 61
8926942 1996
10
[Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IV]. 61
4013323 1985
11
Xanthine oxidase and triglycerides in serum of patients with hyperlipoproteinemia, type IV. 61
6549257 1984
12
Acanthosis nigricans. In association with the adrenogenital syndrome, hyperlipoproteinemia type IV, and congenital malformation of the urinary tract. 61
6639119 1983
13
[Serum lipid concentration in familial hyperlipoproteinemia type IV. Treatment with vitamin C and unsaturated fatty acids]. 61
6871949 1983
14
[High-density lipoprotein cholesterol and the atherogenic index in patients with different types of hyperlipoproteinemias]. 61
6649586 1983
15
[Levels of high-density lipoprotein cholesterol in persons with hypertrigliceridemia-hyperlipoproteinemia type IV]. 61
7170652 1982
16
[Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)]. 61
7047926 1982
17
The effect of weight reduction on biliary lipid metabolism in patients with hyperlipoproteinemia type IV. 61
7311828 1981
18
[Clinical characteristics of primary hyperlipoproteinemia type IV. An analysis of 86 patients]. 61
6963834 1981
19
[Primary hyperlipoproteinemia type IV and V in 3 young children]. 61
7243406 1980
20
Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV. 61
7236016 1980
21
[Study of lipid metabolic coefficient K2 in patients with hyperlipoproteinemia type IV before and after reduction of triglyceride level by adapted diet therapy]. 61
225702 1979
22
[Lipomatosis symetrica benigna with hyperlipoproteinemia type IV and epipharngeal carcinoma]. 61
685365 1978
23
[Coronary artery reserve in patients with hyperlipoproteinemias (author's transl)]. 61
685378 1978
24
[Essential hyperlipoproteinemia type IV (essential endogenous hypertriglyceridemia); clinical and laboratory investigation in 11 patients and their families]. 61
752953 1978
25
[Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)]. 61
227420 1978
26
[Diagnosis of primary hyperlipoproteinemia in umbilical cord blood (author's transl)]. 61
917025 1977
27
[The serum triglycerides and their role as a coronary risk factor (author's transl)]. 61
878547 1977
28
Pseudo-Sjögren syndrome with hyperlipoproteinemia. 61
576655 1977
29
Platelet aggregation and fibrinolytic activity in transient cerebral ischemia. 61
842281 1977
30
[Aseptic necrosis of head of femur and disturbance of fat-metabolism type IIa after Fredrickson (author's transl)]. 61
178115 1976
31
[Musculoskeletal symptoms and hyperlipoproteinemia type IV]. 61
175536 1976
32
[Proceedings: 1. Gout. Acute bullous dermatosis. 2. Latent diabetes mellitus and hyperlipoproteinemia type IV Fredrickson]. 61
769373 1976
33
Prospective study among male employees in industry. I. Prevalence of hyperlipoproteinemia. 61
1166825 1975
34
Plasma glycosphingolipids in diabetics and normals. 61
170451 1975
35
[Diurnal changes in lipoproteins in patients with hyperlipoproteinemia type IV]. 61
179241 1975
36
Bile acid kinetics in relation to sex, serum lipids, body weights, and gallbladder disease in patients with various types of hyperlipoproteinemia;. 61
4373491 1974
37
[Familial hyperlipoproteinemia type IV]. 61
4363634 1974
38
[Liver changes in hyperlipoproteinemia (type IV--Fredrickson's)]. 61
4804709 1973
39
Hyperlipoproteinemia type IV and pre-beta-lipoprotein. Some new aspects of its physiology, pathogenesis and diagnosis. 61
4344735 1972

Variations for Hyperlipoproteinemia, Type Iv

ClinVar genetic disease variations for Hyperlipoproteinemia, Type Iv:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CREB3L3 NM_032607.3(CREB3L3):c.732dup (p.Lys245fs) Duplication Pathogenic 979022 rs780374391 GRCh37: 19:4168364-4168365
GRCh38: 19:4168367-4168368
2 APOA5 NM_001371904.1(APOA5):c.289C>T (p.Gln97Ter) SNV Pathogenic 381733 rs201079485 GRCh37: 11:116661656-116661656
GRCh38: 11:116790940-116790940
3 CREB3L3 NM_032607.3(CREB3L3):c.718G>A (p.Glu240Lys) SNV Likely pathogenic 917849 GRCh37: 19:4168351-4168351
GRCh38: 19:4168354-4168354
4 APOA5 NM_001371904.1(APOA5):c.553G>T (p.Gly185Cys) SNV Uncertain significance 4402 rs2075291 GRCh37: 11:116661392-116661392
GRCh38: 11:116790676-116790676

Expression for Hyperlipoproteinemia, Type Iv

Search GEO for disease gene expression data for Hyperlipoproteinemia, Type Iv.

Pathways for Hyperlipoproteinemia, Type Iv

Pathways related to Hyperlipoproteinemia, Type Iv according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 SLC10A2 LPL LMF1 GPIHBP1 GPD1 CREB3L3
2
Show member pathways
12.63 LPL GPD1 APOA5 APOA2 APOA1
3
Show member pathways
12.53 LPL GPIHBP1 APOE APOC3 APOC2 APOB
4
Show member pathways
12.19 LPL GPIHBP1 APOE APOC3 APOC2 APOB
5
Show member pathways
12.03 LPL LMF1 GPIHBP1 CREB3L3 CETP APOE
6 11.79 APOE APOA5 APOA1
7
Show member pathways
11.77 LPL CETP APOE APOC3 APOC2 APOB
8
Show member pathways
11.67 APOE APOB APOA1
9 11.65 LPL APOC3 APOA5 APOA2 APOA1
10
Show member pathways
11.27 APOB APOA1 ABCG5
11 11.12 APOC3 APOA5 APOA2 APOA1
12 10.9 APOB APOA1
13 10.77 APOA2 APOA1

GO Terms for Hyperlipoproteinemia, Type Iv

Cellular components related to Hyperlipoproteinemia, Type Iv according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.21 LPL GPIHBP1 CETP APOE APOC4 APOC3
2 extracellular space GO:0005615 10.13 LPL CETP APOE APOC3 APOC2 APOB
3 early endosome GO:0005769 9.97 APOE APOC3 APOC2 APOB APOA5 APOA2
4 endoplasmic reticulum lumen GO:0005788 9.89 APOE APOB APOA5 APOA2 APOA1
5 collagen-containing extracellular matrix GO:0062023 9.83 APOE APOC3 APOA1 ANGPTL3
6 chylomicron GO:0042627 9.76 LPL APOE APOC3 APOC2 APOB APOA5
7 low-density lipoprotein particle GO:0034362 9.72 APOE APOC2 APOB APOA5 APOA1
8 blood microparticle GO:0072562 9.71 APOE APOA2 APOA1
9 spherical high-density lipoprotein particle GO:0034366 9.71 APOC3 APOC2 APOA2 APOA1
10 intermediate-density lipoprotein particle GO:0034363 9.65 APOE APOC3 APOC2 APOB APOA1
11 endocytic vesicle lumen GO:0071682 9.63 APOE APOB APOA1
12 high-density lipoprotein particle GO:0034364 9.56 CETP APOE APOC4 APOC2 APOB APOA5
13 discoidal high-density lipoprotein particle GO:0034365 9.51 APOE APOA1
14 very-low-density lipoprotein particle GO:0034361 9.28 LPL APOE APOC4 APOC3 APOC2 APOB

Biological processes related to Hyperlipoproteinemia, Type Iv according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 10.23 LPL CETP APOE APOC4 APOC3 APOC2
2 post-translational protein modification GO:0043687 10.09 APOE APOB APOA5 APOA2 APOA1
3 cellular protein metabolic process GO:0044267 10.07 APOE APOB APOA5 APOA2 APOA1
4 cholesterol metabolic process GO:0008203 10.06 CETP APOE APOB APOA2 APOA1 ANGPTL3
5 triglyceride metabolic process GO:0006641 10.02 LPL LMF1 CETP APOE APOC3 APOA5
6 intermembrane lipid transfer GO:0120009 10.01 CETP APOE APOB APOA2 APOA1 ABCG5
7 lipoprotein metabolic process GO:0042157 10 APOE APOC3 APOB APOA5 APOA2 APOA1
8 steroid metabolic process GO:0008202 9.99 CETP APOE APOB APOA1
9 lipid catabolic process GO:0016042 9.99 LPL APOC3 APOC2 APOB
10 reverse cholesterol transport GO:0043691 9.99 CETP APOE APOC3 APOC2 APOA2 APOA1
11 high-density lipoprotein particle remodeling GO:0034375 9.97 CETP APOE APOC3 APOC2 APOA2 APOA1
12 chylomicron remodeling GO:0034371 9.97 LPL GPIHBP1 APOE APOC3 APOC2 APOB
13 triglyceride catabolic process GO:0019433 9.93 LPL APOC3 APOB APOA5
14 chylomicron assembly GO:0034378 9.93 APOE APOC3 APOC2 APOB APOA2 APOA1
15 cholesterol transport GO:0030301 9.92 CETP APOB APOA2 APOA1
16 cholesterol efflux GO:0033344 9.92 APOE APOC3 APOC2 APOB APOA5 APOA2
17 regulation of lipid metabolic process GO:0019216 9.91 APOA5 APOA2 APOA1
18 low-density lipoprotein particle remodeling GO:0034374 9.91 CETP APOE APOB APOA2
19 high-density lipoprotein particle assembly GO:0034380 9.91 APOE APOA5 APOA2 APOA1
20 phospholipid efflux GO:0033700 9.91 APOE APOC3 APOC2 APOA5 APOA2 APOA1
21 phospholipid metabolic process GO:0006644 9.9 LPL APOA1 ANGPTL3
22 positive regulation of lipoprotein lipase activity GO:0051006 9.9 GPIHBP1 APOC2 APOA5 APOA1
23 lipid homeostasis GO:0055088 9.89 CETP APOE ANGPTL3
24 high-density lipoprotein particle clearance GO:0034384 9.89 APOE APOC2 APOA2 APOA1
25 very-low-density lipoprotein particle remodeling GO:0034372 9.88 LPL CETP APOE APOC2 APOA5 APOA1
26 regulation of lipoprotein lipase activity GO:0051004 9.87 LPL LMF1 GPIHBP1 ANGPTL3
27 positive regulation of cholesterol esterification GO:0010873 9.86 APOE APOA5 APOA2 APOA1
28 retinoid metabolic process GO:0001523 9.86 LPL GPIHBP1 APOE APOC3 APOC2 APOB
29 artery morphogenesis GO:0048844 9.85 APOE APOB ANGPTL3
30 phosphatidylcholine metabolic process GO:0046470 9.85 CETP APOA5 APOA1
31 positive regulation of lipid biosynthetic process GO:0046889 9.85 APOE APOA5 APOA1
32 chylomicron remnant clearance GO:0034382 9.85 APOE APOC3 APOC2 APOB
33 lipid transport GO:0006869 9.85 CETP APOE APOC4 APOC3 APOC2 APOB
34 phospholipid homeostasis GO:0055091 9.84 CETP APOA1 ANGPTL3
35 positive regulation of fatty acid biosynthetic process GO:0045723 9.84 APOC2 APOA5 APOA1
36 very-low-density lipoprotein particle assembly GO:0034379 9.83 APOC4 APOC3 APOB
37 positive regulation of triglyceride catabolic process GO:0010898 9.83 APOC2 APOA5 APOA1
38 positive regulation of lipid catabolic process GO:0050996 9.83 APOA5 APOA2 ANGPTL3
39 regulation of Cdc42 protein signal transduction GO:0032489 9.82 APOE APOC3 APOA1
40 very-low-density lipoprotein particle clearance GO:0034447 9.82 APOE APOC4 APOB
41 lipoprotein biosynthetic process GO:0042158 9.81 APOE APOB APOA1
42 negative regulation of very-low-density lipoprotein particle remodeling GO:0010903 9.8 APOC3 APOA2 APOA1
43 triglyceride-rich lipoprotein particle remodeling GO:0034370 9.79 APOC2 APOA5 APOA2
44 lipid storage GO:0019915 9.74 APOA1 ANGPTL3
45 positive regulation of cholesterol efflux GO:0010875 9.74 APOE APOA1
46 phospholipid catabolic process GO:0009395 9.74 APOA2 ANGPTL3
47 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.74 LPL APOB
48 negative regulation of lipid catabolic process GO:0050995 9.74 APOC3 APOA2
49 positive regulation of lipid storage GO:0010884 9.73 LPL APOB
50 positive regulation of sequestering of triglyceride GO:0010890 9.73 LPL APOC4

Molecular functions related to Hyperlipoproteinemia, Type Iv according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.98 LPL GPD1 CREB3L3 APOE APOA2
2 signaling receptor binding GO:0005102 9.97 LPL APOE APOA2 APOA1 ANGPTL3
3 lipid binding GO:0008289 9.92 GPIHBP1 CETP APOE APOC3 APOC2 APOA5
4 heparin binding GO:0008201 9.91 LPL APOE APOB APOA5 ANGPTL3
5 phospholipid binding GO:0005543 9.88 APOE APOC3 APOB APOA5 APOA2 APOA1
6 cholesterol binding GO:0015485 9.83 CETP APOC3 APOA5 APOA2 APOA1
7 phosphatidylcholine binding GO:0031210 9.78 CETP APOA5 APOA2 APOA1
8 low-density lipoprotein particle receptor binding GO:0050750 9.7 APOE APOB APOA5
9 lipase binding GO:0035473 9.67 GPIHBP1 APOB APOA5
10 lipoprotein particle binding GO:0071813 9.67 LPL GPIHBP1 APOE APOA1
11 lipid transporter activity GO:0005319 9.65 APOE APOC4 APOB APOA2 APOA1
12 high-density lipoprotein particle receptor binding GO:0070653 9.63 APOC3 APOA2 APOA1
13 high-density lipoprotein particle binding GO:0008035 9.59 APOA2 APOA1
14 heparan sulfate proteoglycan binding GO:0043395 9.58 LPL APOE
15 triglyceride binding GO:0017129 9.56 LPL CETP
16 lipoprotein lipase activator activity GO:0060230 9.55 APOC2 APOA5
17 apolipoprotein receptor binding GO:0034190 9.54 APOA2 APOA1
18 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.46 APOE APOA5 APOA2 APOA1
19 lipase inhibitor activity GO:0055102 9.26 APOC3 APOC2 APOA2 APOA1
20 intermembrane cholesterol transfer activity GO:0120020 9.1 CETP APOE APOB APOA2 APOA1 ABCG5

Sources for Hyperlipoproteinemia, Type Iv

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....